HZ-H08905

N/A

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameHZ-H08905
Drug Alias NameHZ-H08905
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitorsCasein kinase I isoform epsilon inhibitors
TargetsPhosphatidylinositol 3 kinase alphaCasein kinase I isoform epsilon
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHeaZen Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHeaZen Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A